Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example

on behalf of the Board of the Metastasis Research Society

Research output: Contribution to journalEditorial

Abstract

This commentary was written as a collaboration between the Board of the Metastasis Research Society and two patients with metastatic breast cancer. It was conceived in response to how preclinical scientific research is sometimes presented to non-scientists in a way that can cause stress and confusion. Translation of preclinical findings to the clinic requires overcoming multiple barriers. This is irrespective of whether the findings relate to exciting responses to new therapies or problematic effects of currently used therapies. It is important that these barriers are understood and acknowledged when research findings are summarized for mainstream reporting. To minimize confusion, patients should continue to rely on their oncology care team to help them interpret whether research findings presented in mainstream media have relevance for their individual care. Researchers, both bench and clinical, should work together where possible to increase options for patients with metastatic disease, which is still in desperate need of effective therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)443-447
Number of pages5
JournalClinical and Experimental Metastasis
Volume34
Issue number8
DOIs
StatePublished - Dec 1 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • Metastatic progression
  • Neoadjuvant chemotherapy
  • Relapse
  • Survival

Fingerprint Dive into the research topics of 'Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example'. Together they form a unique fingerprint.

  • Cite this